PDCD1 and posterior cortical atrophy: However, prostate cancer is known to be insensitive to immunotherapy, and the clinical activity of anti-PD-1 antibodies in unselected PCa is modest.[16] To select patients who can benefit from immunotherapy, individualized treatment has been practiced for metastatic PCa, especially metastatic castration-resistant prostate cancer.